Clinical Trial Update: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. [Phase 2, Phase 3]

View source ↗

Summary

Phase II randomized study comparing BR-DHAP vs R-DHAP induction therapy in relapsed/refractory diffuse large B-cell lymphoma patients eligible for transplantati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• BR-DHAP
• R-DHAP

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2, Phase 3 | Status: COMPLETED